Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin in Advanced HER2-positive Paget's Disease
NCT06561555Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in Paget's disease of the breast, extramammary Paget's disease (EMPD), sponsored by Fudan University. Started Aug 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Paget's disease of the breastextramammary Paget's disease (EMPD)
Beyond the preview
Go deeper on NCT06561555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561555.